Generating #RWE in #SpinalMuscularAtrophy (#SMA) faces hurdles with evolving standard of care, inconsistent outcomes measurement, severity baseline, and the need for long-term follow-up. Test your objectives with us: buff.ly/Qj6Z6Uq

#HCRU #SpinalCare #RealWorldEvidence

Season's greetings from PHARMO, part of Lumanity!

We wish you and your loved ones a peaceful, bright, and joyous season.

#Sinterklaas is celebrated in the Netherlands on December 5, a holiday where creativity plays a key role and is all about bringing people together and creating a warm, festive atmosphere. Yesterday our Utrecht celebrated with second hand gifts and a dice game! #FijneSinterklaas

A recent study in #PrimaryCare #Diabetes underlines the importance of further research into the underlying causes of #glycaemic control disparities and the development of tailored interventions to optimise #T2D care for all. buff.ly/sQaz2P3

#Type2Diabetes #HealthEquity

Check out this article using the PHARMO Data Network to conduct a #retrospective, #observational cohort study to assess a number of clinically relevant endpoints in patients in the Netherlands with #T2D. buff.ly/mSfkk3P

#Type2Diabetes #Diabetes #RWE #Semaglutide

ICYMI, our latest whitepaper explores the growing need for #EvidenceTransportability. Dive into common use cases, challenges in applying non-local data, and our structured framework: buff.ly/LCS7MjB

#RWE #HTA #JCA #StakeholderEngagement #DataValidation

Our latest whitepaper explores the growing need for #EvidenceTransportability, use cases, challenges in applying non-local data, and our framework to effectively assess and enable it buff.ly/LCS7MjB

#RWE #HTA #JCA #StakeholderEngagement #DataValidation

Our latest co-authored publication using #GPData from the PHARMO Data Network, investigates the incidence and natural course of #SHT in #PrimaryCare and assesses guideline adherence and recommendations in Dutch primary care pubmed.ncbi.nlm.nih.gov/41196264/

#Epidemiology #Hyperthyroidism

#ISPOREurope2025 is just days away! Meet with our #RWE experts and discover how leveraging the PHARMO data network can strengthen your HTA submissions with robust, real world insights. buff.ly/z6680ml

#ISPOREurope #HEOR #HealthEconomics #HTA #RWE #RWD

Download our new paper to explore the growing need for #EvidenceTransportability, common use cases, the challenges in applying non-local data, and our structured framework. buff.ly/LCS7MjB

#RWE #EvidenceTransportability #HTA #JCA #StakeholderEngagement #DataValidation

Will you be at #ISPOREurope2025? If so, be sure to catch our poster presentations and connect with our colleagues on-site! Schedule a meeting with us: buff.ly/kvJzMV0

#ISPOREurope #HEOR #HealthEconomics #HTA #RWE #ObservationalStudies #RWD

PHARMO has been addressing design and data biases and applying the #TargetTrialEmulation (#TTE) framework for 25+ years. buff.ly/YsgKNaz

Let's discuss how we can solve your research needs, and be sure to catch us at #ISPOREU2025!

#ObservationalStudies #RCTs #RWE #RWD

Attending the World Vaccine Congress Europe in Amsterdam this week?

Be sure to connect with our colleague Josine Kuiper while at the congress. Learn more at www.terrapinn.com/conference/w...

#WVCEU #WorldVaccineCongress #Vaccines #Biotech

In the Netherlands, an estimated 1,500–2,000 individuals are living with #SickleCellDisease (SCD), yet there's limited #RealWorldData on the clinical burden, especially regarding recurrent vaso-occlusive crisis. Learn more at buff.ly/5PNBMxr

#SickleCellAwareness #RWE

Will you be at the World Vaccine Congress Europe in Amsterdam?

If so, be sure to reach out to Josine Kuiper or email [email protected] to connect while at the conference. Learn more at www.terrapinn.com/conference/w...

#WVCEU #WorldVaccineCongress #Vaccines #Biotech

#TargetTrialEmulation (#TTE) framework can be applied to #ObservationalStudies to emulate the conditions and protocol of an ideal hypothetical #RCT, addressing sources of bias. Learn more about how PHARMO has been doing this for 25+ years. buff.ly/YsgKNaz #RWE #RWD